Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The report for the ROMA (Ovarian Malignancy Risk Algorithm) Test can be obtained within 5-7 business days from the date of sample collection.

What are the prerequisites for the test ROMA (Ovarian Malignancy Risk Algorithm) Test

  • Age: Women aged 18 years and older
  • Postmenopausal or premenopausal status
  • Presence of an ovarian mass
  • CA-125 levels
  • Menopausal status (premenopausal or postmenopausal)

What are the measure values for the test ROMA (Ovarian Malignancy Risk Algorithm) Test

  • Serum CA-125 (U/mL)
  • Human epididymis protein 4 (HE4) (pmol/L)
  • Menopausal status (pre or post)

What does this test ROMA (Ovarian Malignancy Risk Algorithm) Test identify?

ROMA Test

The ROMA (Ovarian Malignancy Risk Algorithm) Test is a blood test that helps identify the risk of ovarian cancer in women. This test combines the results of two blood tests - CA-125 and HE4 - with the patient's menopausal status to calculate the risk of ovarian cancer. The ROMA Test is primarily used to assess the likelihood of malignancy in women with ovarian masses before surgery.

Why is this test ROMA (Ovarian Malignancy Risk Algorithm) Test taken?

The ROMA (Ovarian Malignancy Risk Algorithm) Test is taken to assess the risk of ovarian cancer in women who have a pelvic mass. This test combines the results of two blood tests – CA-125 and HE4 – along with the menopausal status of the woman to calculate a risk score for ovarian cancer.

The ROMA Test is useful in determining whether a woman with a pelvic mass is at low or high risk for ovarian cancer, which can help guide further diagnostic testing and treatment decisions. It is particularly helpful in distinguishing between benign and malignant ovarian tumors, as well as in monitoring the response to treatment in women with ovarian cancer.

No FAQs available.

Customer Google Rating